Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could reveal hidden immune cells in blood vessel disease

NCT ID NCT07269938

Knowledge-focused Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will use a special scan to look for B cells (a type of immune cell) in the blood vessels of 30 people with giant cell arteritis, a serious disease that can cause blindness or stroke. Current treatments rely on steroids, which have harsh side effects. If the scan works, it could lead to trials of targeted B-cell therapies as safer alternatives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

For GCA group: 1. Adults ≥ 50 years at the time of enrolment 2. Meets 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis 3. Imaging evidence of active LV-GCA in the previous 4 weeks 4. Will be managed with corticosteroid monotherapy by the standard care team. For BCMID group: 1. Adults ≥ 18 years at the time of enrolment 2. Meets criteria for a diagnosis of a B-cell mediated immune disorder 3. Considered to have active disease by referring team 4. Will be managed as per standard of care by referring team For AA group: 1. Adults ≥ 50 years at the time of enrolment 2. Imaging evidence of atherosclerotic aortic aneurysm

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For GCA group: 1. Adults ≥ 50 years at the time of enrolment 2. Meets 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis 3. Imaging evidence of active LV-GCA in the previous 4 weeks 4. Will be managed with corticosteroid monotherapy by the standard care team. For BCMID group: 1. Adults ≥ 18 years at the time of enrolment 2. Meets criteria for a diagnosis of a B-cell mediated immune disorder 3. Considered to have active disease by referring team 4. Will be managed as per standard of care by referring team For AA group: 1. Adults ≥ 50 years at the time of enrolment 2. Imaging evidence of atherosclerotic aortic aneurysm Exclusion Criteria: 1. Participants receiving corticosteroids for \>4 weeks immediately prior to baseline 2. Previous diagnosis of GCA 3. History of any major morbidity which the clinical investigator considers contraindicated to study entry 4. Pregnancy or breastfeeding 5. Advanced renal dysfunction (eGFR \<15ml/min/1.73m2) 6. Patients without mental capacity or willingness to provide informed consent 7. Inability or unwillingness to comply with the radiation protection advice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerotic aortic aneurysm are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic aneurysm Giant Cell Arteritis temporal arteritis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Giant cell arteritis (GCA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Edinburgh

    Edinburgh, City Of Edinburgh, EH16 4TJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.